Disk diffusion testing of susceptibility of Mycobacterium fortuitum and Mycobacterium chelonei to antibacterial agents.

Antimicrobial Agents and Chemotherapy
Richard J WallaceG A Pankey

Abstract

Although recent studies have suggested that some antibacterial agents have good activity against the rapidly growing mycobacteria Mycobacterium fortuitum and Mycobacterium chelonei, an easily applicable method for susceptibility testing of clinical isolates is not yet available. We evaluated a disk diffusion method with Mueller-Hinton agar and 48-h readings with 59 strains of M. fortuitum and 11 strains of M. chelonei and compared the results to agar dilution susceptibilities for nine antimicrobial agents. All isolates were susceptible to 16 micrograms of amikacin or kanamycin per ml with minimum zone diameters of 14 and 18 mm, respectively. Amikacin inhibited 100% of isolates of M. fortuitum at 2 micrograms/ml, whereas 10 of 11 (91%) of M. chelonei strains had minimum inhibitory concentrations of 4.0 micrograms/ml or greater. Doxycycline and minocycline had almost identical activities, inhibiting 44% of strains at 4.0 micrograms/ml, and both allowed easy differentiation between susceptible and resistant strains by disk diffusion. Although most isolates of M. chelonei grew better on 7H10 agar, this media gave two- to eight-fold higher minimum inhibitory concentrations than were obtained with Mueller-Hinton agar. Disk diffusion ...Continue Reading

References

Jun 1, 1979·Antimicrobial Agents and Chemotherapy·D F Welch, M T Kelly
Mar 1, 1978·The Journal of Infectious Diseases·J R Dalovisio, G A Pankey
Feb 1, 1971·The Journal of Infectious Diseases·A Molavi, L Weinstein

❮ Previous
Next ❯

Citations

May 1, 1991·Research in Microbiology·H Nikaido, V Jarlier
Jan 1, 1987·The Journal of Infection·P McIntyreJ G McCormack
May 1, 1987·Journal of the American Academy of Dermatology·S A Lazo-de-la-VegaG M Ruiz-Palacios
Nov 1, 1996·The Pediatric Infectious Disease Journal·R K AveryM S Pasternack
Aug 1, 1992·Australian and New Zealand Journal of Ophthalmology·J GriggP Gnanaharan
Aug 19, 2004·ANZ Journal of Surgery·John C MuthusamiS R Banerjee Jesudason
Jan 1, 1981·Antimicrobial Agents and Chemotherapy·M H Cynamon, A Patapow
Nov 1, 1981·Antimicrobial Agents and Chemotherapy·R J Wallace, K Wiss
Aug 1, 1982·Antimicrobial Agents and Chemotherapy·J M SwensonV A Silcox
Feb 1, 1985·Antimicrobial Agents and Chemotherapy·M J CasalM C Benavente
Jul 6, 2012·Clinical Microbiology Reviews·Barbara A Brown-ElliottRichard J Wallace
May 1, 1983·The British Journal of Ophthalmology·D J MirateM J Carter
Aug 24, 2013·Emerging Infectious Diseases·Mihaela IvanChris Lease
Jul 15, 1986·American Journal of Ophthalmology·J B RobinR E Smith
Oct 15, 1986·American Journal of Ophthalmology·M B MooreH E Kaufman
Apr 15, 1989·American Journal of Ophthalmology·T J RousselJ P Whitcher
Mar 1, 1984·American Journal of Ophthalmology·P E NewmanH D Cavanagh
Sep 1, 1982·American Journal of Ophthalmology·D M MeislerM Okumoto
Jul 1, 1991·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·R B Dunmire, J A Breyer
Feb 1, 1985·Chest·R J WallaceV Silcox
Apr 25, 2012·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·Jakko van IngenJohan W Mouton
Oct 1, 1985·Zentralblatt Für Bakteriologie, Mikrobiologie, Und Hygiene. Series A, Medical Microbiology, Infectious Diseases, Virology, Parasitology·I N de KantorM di Lonardo
Oct 1, 1995·Zentralblatt Für Bakteriologie : International Journal of Medical Microbiology·W FabryR Ansorg
Mar 17, 2009·International Journal of Antimicrobial Agents·H FooG L Gilbert
Nov 3, 2004·The Journal of Small Animal Practice·R MalikC Gilpin
Mar 1, 1984·Tubercle·V AusinaG Prats
Jul 1, 1985·The Journal of Dermatologic Surgery and Oncology·D D MadjarN A Fenske
Mar 1, 1997·Clinics in Chest Medicine·L Heifets
Oct 15, 1994·FEMS Microbiology Letters·V Jarlier, H Nikaido
Oct 27, 2016·BMC Infectious Diseases·Thilini Piushani KeerthirathneSuneth Sithumini Sooriyapathirana
Mar 21, 2017·International Journal of Mycobacteriology·Roumi GhoshPrasanta Kumar Maiti
May 1, 1996·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·A MorenoN Batista

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.